- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT05647564
PET/CT Charakterystyka oporności na leczenie
PET/CT Charakterystyka oporności na leczenie terapii ukierunkowanych na AR w mCRPC
This study will use different types of medical imaging to assess how lesions from advanced prostate cancer become resistant to second-generation AR-targeted therapy, and how the different types of imaging compare in that assessment. Participants in this study have advanced prostate cancer and are either scheduled to start a second-generation androgen receptor (AR) targeted therapy (such as enzalutamide, abiraterone, or apalutamide) or are already being treated with one. Participants can expect to be in the study for at least 9 months, and up to 2 years.
Przegląd badań
Status
Warunki
Szczegółowy opis
There are two groups, or cohorts, in this study. Participants are assigned to Cohort A if they have advanced prostate cancer and are scheduled to start a second-generation AR-targeted therapy (such as enzalutamide, abiraterone, darolutamide, or apalutamide) or PSMA directed radiotherapy (e.g. Lu177-PSMA radio-ligand therapy. Participants are assigned to Cohort B if they have advanced prostate cancer, are already on a second-generation AR-targeted therapy, and have shown an increase in their PSA (prostate-specific antigen) levels.
There are two medical imaging scans that will be done for research purposes in this study. One is called 18F-fluorodeoxyglucose positron emission tomography (FDG PET) and the other is prostate-specific membrane antigen positron emission tomography (PSMA PET). These scans are done simultaneously with computed tomography (CT) scanning. Participants will be scheduled to have 6 scans, 3 FDG PET/CT scans and 3 PSMA PET/CT scans.
Typ studiów
Zapisy (Szacowany)
Faza
- Nie dotyczy
Kontakty i lokalizacje
Kontakt w sprawie studiów
- Nazwa: Cancer Connect
- Numer telefonu: 800-622-8922
- E-mail: clinicaltrials@cancer.wisc.edu
Lokalizacje studiów
-
-
Wisconsin
-
Madison, Wisconsin, Stany Zjednoczone, 53705
- Rekrutacyjny
- University of Wisconsin
-
Kontakt:
- Cancer Connect
- Numer telefonu: 800-622-8922
- E-mail: clinicaltrials@cancer.wisc.edu
-
Główny śledczy:
- John Floberg, MD, PhD
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- Histologically proven adenocarcinoma of the prostate.
- At least 1 radiographic metastases as seen on conventional CT imaging or bone scan
- Progressive prostate cancer as evident by at least two separate increase in PSA over nadir, and absolute PSA value at least 2 ng/ml (INTRINSIC RESISTANCE COHORT, ARSI patients ONLY)
- Patients must be candidate for a second-generation androgen receptor (AR) inhibitor (e.g. enzalutamide, abiraterone, darolutamide, apalutamide), or Lu177-PSMA radioligand therapy (INTRINSIC RESISTANCE COHORT ONLY)
- Men of age >18 years.
- Patients must be able to comply with all study procedures, including having both the ability and willingness to lie flat for ≥ 30 minutes during imaging
- Patients must be informed of the exploratory nature of the study and its potential risks, and must sign IRB-approved consent form indicating such understanding.
- Life-expectancy at least 12 months
- Patients currently receiving a second-generation androgen receptor (AR) inhibitor (e.g. enzalutamide, abiraterone, darolutamide, apalutamide) and must have had 1) PSA decline on treatment and 2) now have PSA increase over nadir while still on treatment (patients must be registered within 12 weeks of first documented PSA increase) (ACQUIRED RESISTANCE COHORT ONLY)
Exclusion Criteria:
- Must not have uncontrolled diabetes (fasting blood sugar > 200 mg/dL or inability to safely hold diabetes medication or fast 6 hours prior to FDG PET scan)
- Prior treatment with second-generation AR inhibitor for prostate cancer in the metastatic disease setting (prior second-generation AR inhibitor in the neoadjuvant or adjuvant setting is permitted unless patient developed progression while on treatment) (INTRINSIC RESISTANCE COHORT, AR-INHIBITOR GROUP ONLY)
- Pain or clinical symptoms from metastatic prostate cancer requiring opioid analgesics
- Known neuro-endocrine prostate cancer
- Prior radioisotope therapy for castration-resistant prostate cancer
- To avoid the possibility of unintended coercion, vulnerable populations such as incarcerated subjects, subjects unable to provide their own informed consent and non-English speaking patients will not be considered
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Diagnostyczny
- Przydział: Nielosowe
- Model interwencyjny: Przydział równoległy
- Maskowanie: Brak (otwarta etykieta)
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Inny: Intrinsic Resistance Cohort (Cohort A)
Participants assigned to Cohort A have advanced prostate cancer and are scheduled to start a second-generation AR-targeted (such as enzalutamide, abiraterone, darolutamide, or apalutamide) or PSMA directed (e.g. Lu177-PSMA) therapies . |
Imaging scan Imaging scan |
|
Inny: Acquired Resistance Cohort (Cohort B)
Participants are assigned to Cohort B if they have advanced prostate cancer, are already on a second-generation AR-targeted therapy, and have shown an increase in their PSA (prostate-specific antigen) levels. |
Imaging scan Imaging scan |
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Characterize intrinsic resistance based on FDG and PSMA PET through change in individual lesion update levels.
Ramy czasowe: Baseline to 12 weeks
|
Changes in individual lesion update levels (ΔiSUVtotal) will be calculated. SUVtotal is a metric of activity, for which less activity is better. |
Baseline to 12 weeks
|
|
Characterize change in intrinsic resistance based on FDG and PSMA PET.
Ramy czasowe: Baseline to 12 weeks
|
Changes in individual lesion update levels (ΔiSUVtotal) will be calculated. SUVtotal is a metric of activity, for which a decrease in activity is better. |
Baseline to 12 weeks
|
|
Characterize change in intrinsic resistance based on FDG and PSMA PET.
Ramy czasowe: 12 weeks to 36 weeks
|
Changes in individual lesion update levels (ΔiSUVtotal) will be calculated. SUVtotal is a metric of activity, for which a decrease in activity is better. |
12 weeks to 36 weeks
|
|
Characterize change in intrinsic resistance based on FDG and PSMA PET.
Ramy czasowe: Baseline to 36 weeks
|
Changes in individual lesion update levels (ΔiSUVtotal) will be calculated. SUVtotal is a metric of activity, for which a decrease in activity is better. |
Baseline to 36 weeks
|
|
Characterize acquired resistance at the time of progression
Ramy czasowe: Baseline to 36 weeks
|
Percentage and absolute changes in individual lesion update levels (ΔiSUVtotal) will be calculated. |
Baseline to 36 weeks
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Correlate amount of intrinsic resistance on FDG and PSMA PET to predict time to PSA progression
Ramy czasowe: Baseline to 36 weeks
|
Analysis will be conducted to evaluate whether changes in lesion uptake values predict time to PSA progression. PSA progression will be 25% increase and >2 ng/mL above PSA nadir |
Baseline to 36 weeks
|
|
Correlate amount of intrinsic resistance on FDG and PSMA PET to predict time to radiographic progression
Ramy czasowe: Baseline to 36 weeks
|
Analysis will be conducted to evaluate whether changes in lesion uptake values predict time to radiographic progression. Time to radiographic progression will be defined as the number of days to confirmed radiographic progression using Prostate Cancer WorkingGroup 3 (PCWG3) criteria. |
Baseline to 36 weeks
|
|
Correlate amount of intrinsic resistance on FDG and PSMA PET to predict time duration on treatment
Ramy czasowe: Up to 36 weeks
|
Analysis will be conducted to evaluate whether changes in lesion uptake values predict duration of treatment. Duration of treatment will be defined as the time from treatment start, to treatment discontinuation (and reason for discontinuation) using PCWG3 criteria. |
Up to 36 weeks
|
Współpracownicy i badacze
Sponsor
Śledczy
- Główny śledczy: Glenn Liu, MD, University of Wisconsin, Madison
- Główny śledczy: Robert Jeraj, PhD, University of Wisconsin, Madison
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Zakończenie podstawowe (Szacowany)
Ukończenie studiów (Szacowany)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
- 2022-0910
- A534260 (Inny identyfikator: UW Madison)
- 2022-0910 (Inny identyfikator: UW Madison)
- SMPH/MEDICINE/HEM-ONC (Inny identyfikator: UW Madison)
- NCI-2022-09580 (Identyfikator rejestru: NCI)
- Protocol Version 8/1/2026 (Inny identyfikator: UW Madison)
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
produkt wyprodukowany i wyeksportowany z USA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .